Description

Tesamorelin (Synthetic Growth Hormone‑Releasing Hormone Analog)

Description

• Tesamorelin is a synthetic analog of growth hormone‑releasing hormone (GHRH) that stimulates pulsatile release of endogenous growth hormone (GH).
• Used clinically to reduce visceral adipose tissue in specific indications and studied for metabolic and aging‑related research.

Key benefits

• Reduces visceral abdominal fat in treated populations (documented in clinical trials).
• Improves body composition by decreasing central adiposity while preserving or modestly increasing lean mass.
• Indirectly influences metabolic processes via stimulated endogenous GH secretion.

Primary uses

• FDA‑approved indication (where applicable): reduction of excess visceral adipose tissue in HIV‑infected adults with lipodystrophy.
• Investigational/clinical research uses: exploring effects on metabolic health, body composition, and age‑related declines in GH axis under controlled protocols.

Who it’s for

• Patients prescribed tesamorelin by a qualified clinician for approved indications (e.g., HIV‑associated visceral adiposity) and participants in controlled clinical trials.
• Not intended for unsupervised cosmetic or athletic use.

Suggested use

• Administered by subcutaneous injection per prescribing information or clinical protocol; dosing and duration determined by indication and clinician.
• Regular monitoring of IGF‑1, glucose metabolism, and clinical response is recommended during therapy.
• Follow clinician instructions for titration, storage, and injection technique.

Safety and storage

• Common adverse effects: injection‑site reactions, arthralgia, myalgia, peripheral edema, and potential increases in IGF‑1.
• Metabolic effects: may impair glucose tolerance or raise fasting glucose in some patients; monitor glycemic status, especially in those with diabetes or prediabetes.
• Contraindications/precautions: active malignancy, hypersensitivity to the product, and caution in patients with severe or uncontrolled medical conditions; discuss personal/family cancer history with your clinician.
• Store refrigerated as directed by manufacturer; handle and dispose of needles/syringes per local regulations.

Quick facts

• Mechanism: GHRH receptor agonism → stimulates endogenous pulsatile GH release and downstream IGF‑1 production.
• Regulatory status: approved for specific indications in some regions; investigational for other uses—use only under prescription or within approved trials.
• Not a substitute for GH therapy; acts by stimulating physiological GH secretion rather than providing exogenous GH.

Research Use Only Disclaimer

Products sold by SoCo Peptides are intended strictly for laboratory research purposes only.

These compounds are not intended for human consumption, veterinary use, household use, cosmetic use, or therapeutic application. They are not drugs, foods, or dietary supplements and have not been evaluated or approved by the FDA.

By purchasing from this website, the customer represents that they are a qualified researcher or laboratory professional and understand the risks associated with handling research materials.

All products must be handled by trained professionals in appropriate research facilities and in accordance with all applicable laws and regulations.

SoCo Peptides makes no guarantees or claims regarding safety, effectiveness, or medical benefit.